Publications

Starling BR, Kumar P, Lucas AT, Barroa D, Farnan L, Hendrix L, Giovinazzo H, Song G, Gehrig P, Benson J, Zamboni WC. 2019. Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemother Pharmacol 83(1):61–70.

Storm HM, Shepard J, Czerkies LM, Kineman B, Cohen SS, Reichert H, Carvalho R. 2019. 2’-Fucosyllactose is well tolerated in a 100% whey, partially hydrolyzed infant formula with Bifidobacterium lactis: A randomized controlled trial. Global Pediat Health 6:1–10. DOI: 10.1177/2333794X19833995.

Suh M, Wikoff D, Lipworth L, Goodman M, Fitch S, Mittal L, Ring C, Proctor D. 2019. Hexavalent chromium and stomach cancer: A systematic review and meta-analysis. Crit Rev Toxicol [ePub ahead of print]: doi: 10.1080/10408444.2019.1578730.

Rager JE, Suh M, Chappell G, Thompson CM, Proctor DM. 2019. Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. Toxicol Lett 305:40-50.

Wikoff DS, Rager JE, Chappell GA, Fitch S, Haws L, Borghoff SJ. 2019. A framework for systematic evaluation and quantitative integration of mechanistic data in assessments of potential human carcinogens. Toxicol Sci 167(2):322-335.

Suh M, Casteel S, Dunsmore M, Ring C, Verwiel A, Proctor DM. 2019. Bioaccessibility and relative oral bioavailability of cobalt and nickel in residential soil and dust affected by metal grinding operations. Sci Tot Environ 660:677–689.

Borghoff SJ, Fitch S, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99:168–181.

Harrill AH, Borghoff S, Zorrilla L, Blystone C, Kissling GE, Malarkey D, Shockley K, Travlos G, DeVito MJ. 2018. NTP Research Report on baseline characteristics of Diversity Outbred (J:DO) mice relevant to toxicology studies. National Toxicology Program Research Report 6, Research Triangle Park, NC.

Klaren WD, Ring C, Harris MA, Thompson CM, Borghoff S, Sipes NS, Hsieh J-H, Auerbach SS, Rager JE. 2018. Identifying attributes that influence in vitro-to-in vivo concordance by comparing in vitro Tox21 bioactivity versus in vivo DrugMatrix transcriptomic responses across 130 chemicals. Toxicol Sci kfy220, available at https://doi.org/10.1093/toxsci/kfy220.

Wikoff DS, Thompson C, Rager J, Chappell G, Fitch S, Doepker C. 2018. Benefit-risk analysis for foods (BRAFO): Evaluation of exposure to dietary nitrates. Food Chem Toxicol 120:709-723.

Moffat I, Martinova N, Seidel C, Thompson CM. 2018. Hexavalent chromium in drinking water. Journal AWWA 110:5.

Phillips MB, Balbuena-Venancio P, Enders JR, Norini RL, Shim Y-S, Burgunder E, Rao L, Billings D, Pedersen J, Macdonald JM, Andersen M, Clewell HJ 3^rd, Yoon M. 2018. Xenobiotic metabolism in alginate-encapsulated primary human hepatocytes over long timeframes. Appl in Vitro Toxicol 4(3), DOI: https://doi.org/10.1089/aivt.2017.0029.

Wikoff DS, Miller GW. 2018. Systematic reviews in toxicology (Editorial). Toxicol Sci 163(2):335–337.

Hartman JK, Beames T, Parks B, Doheny D, Song G, Efremenko A, Yoon M, Foley B, Deisenroth C, McMullen PD, Clewell RA. 2018. An in vitro approach for prioritization and evaluation of chemical effects on glucocorticoid receptor mediated adipogenesis. Toxicol Appl Pharmacol 355:112-126.

Thompson CT, Suh M, Chappell G, Borghoff S, Ellis-Hutchings, R, Wiench, K, Finch, L, Proctor, DM. 2018. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. Regul Toxicol Pharmacol 96:178–189 doi: 10.1016/j.yrtph.2018.05.006.

Suh M, Proctor DM, Chappell G, Rager JE, Thompson CM, Borghoff S, Finch L, Ellis-Hutchings R, Wiench K. 2018. A review of the genotoxic, mutagenic, and carcinogenic potentials of several lower acrylates. Toxicology 402-403:50-67, doi: 10.1016/j.tox.2018.04.006.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96:30-40, doi: 10.1016/j.yrtph.2018.04.016.

Hedges L, Brown S, Vardy A, Doyle E, Yoon M, Osimitz TG, Lake BG. 2018. Metabolism of deltamethrin and cis- and trans-permethrin by rat and human liver microsomes, liver cytosol and plasma preparations. Xenobiotica published online. Doi: 10.1080/00498254.1451011.

Campbell JL Jr, Yoon M, Ward PL, Fromme H, Kessler W, Phillips MB, Anderson WA, Clewell HJ 3rd, Longnecker MP. 2018. Excretion of di-2-ethylhexyl phthalate (DEHP) metabolites in urine is related to body mass index because of higher energy intake in the overweight and obese. Environ Int 113:91–99. doi:10.1016/j.envint.2018.01.023.

Song G, Van Landingham CB, Gentry PR, Taylor MD, Keene AM, Andersen ME, Clewell HJ, Yoon M. 2018. Physiologically-based pharmacokinetic modeling suggests similar bioavailability of Mn from diet and drinking water. Tox Appl Pharmacol 359:70–81.

McMullen PD, Andersen ME, Cholewa B, Clewell HJ 3rd, Dunnick K, Hartman J, Mansouri K, Minto MS, Nicolas CI, Phillips M, Slattery S, Yoon M, Clewell RA. 2018. Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. Toxicol In Vitro 48:310-317.  DOI: 10.1016/j.tiv.2018.01.027.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Wikoff D, Urban JD, Harvey S, Haws LC. 2018. Role of risk of bias in systematic review for chemical risk assessment: A case study in understanding the relationship between congenital heart defects and exposures to trichloroethylene. Int J Toxicol, DOI: 0.1177/1091581818754330.

Doepker C, Franke K, Myers E, Goldberger JJ, Lieberman HR, O’Brien C, Peck J, Tenenbein M, Weaver C, Wikoff D. 2018. Key findings and implications of a recent systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Nutrients 10:1536, doi: 10.3390/nu10101536.

Rish W, Pfau EJ. 2018. Bounding analysis of drinking water health risks from a spill of hydraulic fracturing flowback water. Risk Analysis 38(4):724-754, DOI: 10.1111/risa.12884.

Lansita J,  Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. 2017. Nonclinical development of ANX005: A humanized anti-Clq antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol 1-14. DOI: 10.1177/1091581817740873.

Rager JE, Auerbach SS, Chappell GA, Martin E, Thompson C, Fry RC. 2017. Benchmark dose modeling estimates of the concentrations of inorganic arsenic that induce changes to the neonatal transcriptome, proteome, and epigenome in a pregnancy cohort. Chem Res Toxicol 30(10):1911-1920; DOI: 10.1021/acs.chemrestox.7b00221.

Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA. 2017. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. Mutation Res 823:45-57.

Thompson CM, Young RR, Dinesdurage H, Suh M, Harris MA, Rohr AC, Proctor DM. 2017. Assessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats. Toxicol Appl Pharmacol 330(1):48-52.

Ring CL, Pearce RG, Setzer RW, Wetmore BA, Wambaugh JF. 2017. Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. Environ Int 106:105–118.

Chappell GA, Rager JE. 2017. Epigenetics in chemical-induced genotoxic carcinogenesis. Current Opinion Toxicol 6:10-17.

Bichteler A, Wikoff DS, Loko F, Harris MA. 2017. Estimating serum concentrations of dioxin-like compounds in the U.S. population effective 2005-2006 and 2007-2008: A multiple imputation and trending approach incorporating NHANES pooled sample data. Environ Int 105(2017):112-125.

Hoffmann S, de Vries RB, Stephens ML, Beck NB, Dirven HAAM, Fowle III JR, Goodman JE, Hartung T, Kimber I, Lalu MM, Thayer K, Whaley P, Wikoff D, Tsaioun K. 2017. A primer on systematic reviews in toxicology. Arch Toxicol DOI: 10.1007/s00204-017-1980-3.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212. https://doi.org/10.1093/toxsci/kfx085

Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, Goldberger J, Lieberman HR, O’Brian C, Peck J, Tenebein M, Weaver C, Harvey S, Urban J, Doepker C. 2017. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol 109(Pt1):585-648. https://doi.org/10.1016/j.fct.2017.04.002.

Ramoju SP, Mattison DR, Milton B, McGough D, Shilnikova N, Clewell HJ, Yoon M, Taylor MD, Krewski D, Andersen ME. 2017. The application of PBPK models in estimating human brain tissue manganese concentrations. Neurotoxicology 58:226–237.

Ruark CD, Song G, Yoon M, Verner MA, Andersen ME, Clewell HJ 3rd, Longnecker MP. 2017. Quantitative bias analysis for epidemiological associations of perfluoroalkyl substance serum concentrations and early onset of menopause. Environ Int 99:245–254.

Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, Creek MR, Clewell HJ, Yoon M. 2017. Determination of human hepatic CYP2C8 and CYP1A2 age-dependent expression to support human health risk assessment for early ages. Drug Metab Disposit 45(5):468–475

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325:9-17.

Welsh BT, Todorovic J, Kirson D, Allen HM, Bayly MD, Mihic SJ. 2017. Disruption of a putative intersubunit electrostatic bond enhances agonist efficacy at the human α1 glycine receptor. Brain Res 1657:148-155. 

View Abstract

Mease K, Kimzey A, Lansita J. 2017. Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design. Curr Opin Toxicol (4:1–15).

Ngueta G, Longnecker MP, Yoon M, Ruark CD, Clewell HJ Rd, Andersen ME, Verner MA. 2017. Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. Environ Int 104:118–121.

Moreau M, Leonard J, Phillips K, Campbell J, Pendse S, Nicolas C, Phillips M, Yoon M, Tan Y-M, Smith S, Pudukodu H, Isaacs K, Clewell H. 2017. Using exposure prediction tools to link exposure and dosimetry for risk-based decisions: A case study with phthalates. Chemosphere 184:1194–1201.

Clippinger AJ, Allen D, Jarabek AM, Corvaro M, Gaça M, Gehen S, Hotchkiss JA, Patlewicz G, Melbourne J, Hinderliter P, Yoon M, Huh D, Lowit A, Buckley B, Bartels M, BéruBé K, Wilson DM, Indans I, Vinken M. 2017. Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicol In Vitro 48:53–70. doi: 10.1016/j.tiv.2017.12.011. PubMed PMID: 2927765

Lucas AT, White TF, Deal AM, Herity LB, Song G, Santos CM, Zamboni WC. 2017. Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. Nanomedicine 13(2):471–482.

Song G, Pacini G, Ahrén B, D’Argenio DZ. 2017. Glucagon effects on insulin clearance in mice: Population modelling analysis. Peptides 88:74–79.

Thompson CM, Wolf, JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA. 2017. Comparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium. Toxicol Pathol 45(8):1091–1101. DOI: 10.1177/019262331yy4324.

Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer KLR, Casey WM, Chjoksi N, Ferguson SS, Fraczkiewicz G, Jarabek AM, Ke A, Lumen A, Lynn SG, Paini A, Price PS, Ring C, Simon TW, Sipes NS. 2017. In vitro to in vivo extrapolation for high throughput prioritization and decision making. Toxicol in Vitro 47:213–227.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genetic Toxicol Environ Mutagen 800-801:28-34.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57:706-716.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol   306:113-119.

Borghoff SJ, Ring C, Banton M, Leavens TL. 2016. Physiologically based pharmacokinetic model for ethyl tertiary-butyl ether and tertiary-butyl alcohol in rats: Contribution of binding to a2u-globulin in male rats and high-exposure nonlinear kinetics to toxicity and cancer outcomes.  J Appl Toxicol, DOI 10.1002/jat.3412

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80:60-70.

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(2016):74-82.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol 306:120-133.

Yoon M, Clewell HJ 3rd. 2016. Addressing early life sensitivity using physiologically based pharmacokinetic modeling and in vitro to in vivo extrapolation. Toxicol Res 32(1):15–20.

Yoon M, Adeleye Y, Clewell R, Jennings P, Whelan M. 2016. Roundtable discussion: Moving beyond prioritization toward true in vitro safety assessment. Appl In Vitro Toxicol 2(2):67–73.

Pedersen JM, Shim YS, Hans V, Phillips MB, Macdonald JM, Walker G, Andersen ME, Clewell HJ 3rd, Yoon M. 2016. Fluid dynamic modeling to support the development of flow-based hepatocyte culture systems for metabolism studies. Front Bioeng Biotechnol 4:72.

Grego S, Dougherty ER, Alexander FJ, Auerbach SS, Berridge BR, Bittner ML, Casey W, Cooley PC, Dash A, Ferguson SS, Fennell TR, Hawkins BT, Hickey AJ, Kleensang A, Liebman MNJ, Martin F, Maull EA, Paragas J, Qiao GG, Ramaiahgari S, Sumner SJ, Yoon M. 2016. Systems biology for organotypic cell cultures. ALTEX 34(2):301–310.

Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC. 2016. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmcol 77(3):565–573.

Song G, Suzuki OT, Santos CM, Lucas AT, Wiltshire T, Zamboni WC. 2016. Gulp1 Is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. Nanomedicine: Nanotechnol, Biol, Med 12(7):2007–2017.

Song G, Peeples CR, Yoon M, Wu H, Verner M-A, Andersen ME, Clewell HJ, Longnecker MP. 2016. Evaluating epidemiological associations between high blood concentrations of polybrominated diphenyl ethers (PBDEs) and altered timing of menarche: Are they meaningful? Environ Res 150:541–548.

Yoon M, Adeleye Y, Clewell R, Jennings P, Whelan M. 2016. Moving beyond prioritization toward true in vitro safety assessment. Appl In Vitro Toxicol 2(2):67–73.

Cullen JM, Ward JM, Thompson CM. 2016. Reevaluation and classification of duodenal lesions in B6C3F1 mice and F344 rats from 4 studies of hexavalent chromium in drinking water. Toxicologic Pathol 44(2):279-89.

Wikoff DS, Britt JK.  2016. The role of systematic review in the practice of toxicology and risk assessment – An appreciation for the primary tool in evidence-based approaches.  Toxicology: Open Access 2(110):1-4. 

Wikoff DS, Rager JE, Haws LC, Borghoff SJ. 2016. A high dose mode of action for tetrabromobisphenol A-induced uterine adenocarcinomas in Wistar Han rats: A critical evaluation of key events in an adverse outcome pathway framework. Regul Toxicol Pharmacol 77:143-159. doi: 10.1016/j.yrtph.2016.01.018

Hanlon P, Brorby GP, Krishan M. 2016. A risk-based strategy for evaluating mitigation options for processed-formed compounds in food: Workshop proceedings. Int J Toxicol 35(3):358–370.

Schmitt D, Levy R, Carroll B. 2016. Toxicological evaluation of ß-caryophyllene oil: Subchronic toxicity in rats. Int J Toxicol 35(5):558–567.

Borghoff SJ, Wikoff D, Harvey S, Haws L. 2016. Dose- and time-dependent changes in tissue levels of tetrabromobisphenol A (TBBPA) and its sulfate and glucuronide conjugates following repeated administration to female Wistar Han Rats. Toxicol Rep 3:190-201. doi:10.1016/j.toxrep.2016.01.007

Doepker C, Lieberman HR, Smith AP, Peck JD, El-Sohemy A, Welsh BT. 2016. Caffeine: Friend or Foe? Annu Rev Food Sci Technol. DOI: 10.1146/annurev-food-041715-033243

Proctor DM, Suh M, Mittal L, Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol 26(2):224-231. doi: 10.1038/jes.2015.77.

James RC, Britt JK, Halmes NC, Guzelian PS. 2015. Evidence-based causation in toxicology: A 10-year retrospective. Hum Exp Toxicol 34(12):1245–1252.

Lansita JA, Burke JM, Apgar JF, Mounho-Zamora B. 2015. An introduction to the regulatory and nonclinical aspects of the nonclinical development of antibody drug conjugates. Pharmceut Res 32(11):3584-3592. DOI 10.1007/s11095-015-1742-y

Thompson CM, Wolf JC, Elbekai RH, Paranjpe MG, Seiter JM, Chappell MA, Tappero RV, Suh M, Proctor DM, Bichteler A, Haws LC, Harris MA. 2015. Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ-H2AX immunostaining, and synchrotron x-ray fluorescence microscopy. Mut Res 789–790:61–66.

Thompson CM, Young RR, Suh M, Dinesdurage HR, Elbekai RH, Harris MA, Rohr AC, Proctor DM. 2015. Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big Blue® transgenic F344 rats. Environ Mol Mutagen 56:621-628.

Young RR, Thompson CM, Dinesdurage HR, Elbekai RH, Suh M, Rohr AC, Proctor DM. 2015. A robust method for assessing chemically induced mutagenic effects in the oral cavity of transgenic Big Blue® rats. Environ Mol Mutagen 56:629-636.

Borghoff SJ, Poet TS, Green S, Davis J, Hughes B, Mensing T, Sarang SS, Lynch AM, Hard GC.  2015. Methyl isobutyl ketone exposure-related increases in specific measures of α2u-globulin (α2u) nephropathy in male rats along with in vitro evidence of reversible protein binding. Toxicology 333(2015):1-13.

Lansita JA, Mounho-Zamora B. 2015. The development of therapeutic monoclonal antibodies:  Overview of the nonclinical safety assessment. Curr Pain Headache Rep 19(3):472.

Urban JD, Carakostas MC, Taylor SL. 2015. Steviol glycoside safety: Are highly purified steviol glycoside sweeteners food allergens? Food Chem Toxicol 75: 71-78.

Yoon M, Clewel H 3rd, Blaauboer BJ (Eds). 2015. Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. Toxicology 332:1–124.

Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC. 2015. Role of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. Nanomedicine: Nanotechnol, Biol, Med 11(7):1979–807.

Petschauer JS, Madden AJ, Kirschbrown WP, Song G, Zamboni WC. 2015. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine 10(3):447–463.

Campbell JL, Yoon M, and Clewell HJ 3^rd. 2015. A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben. Toxicology 332:67–76.

Yoon M, Kedderis GL, Yan GZ, and Clewell HJ 3^rd. 2015. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. Toxicology 332:52–66.

Yoon M, Blaauboer BJ, and Clewell HJ. 2015. Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. An editorial for the Special Issue in Toxicology 332:1–3.

Wu H, Yoon M, Verner MA, Xue J, Luo M, Andersen ME, Longnecker MP, Clewell HJ 3rd. 2015. Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? Environ Int 82:61–68.

Brown K, Phillips M, Grulke C, Yoon M, Young B, McDougall R, Leonard J, Lu J, Lefew W, Tan YM. 2015. Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling—A case study with carbaryl. Regul Toxicol Pharmacol 73(3):689–698.

Verner MA, Loccisano AE, Morken NH, Yoon M, Wu H, McDougall R, Maisonet M, Marcus M, Kishi R, Miyashita C, Chen MH, Hsieh WS, Andersen ME, Clewell HJ 3rd, Longnecker MP. 2015. Associations of perfluoroalkyl substances (PFAS) with lower birth weight: An evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environ Health Persp 123(12):1317–1324.

Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC. 2015. Role of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. Nanomedicine: Nanotechnol, Biol, Med 11(7):1979–807.

Ramani T, Auletta CS, Weinstock D, Mounho-Zamora B, Ryan PC, Salcedo TW, Bannish G. 2015. Cytokines: The good, the bad, and the deadly. Int J Toxicol 34(4):355–365, DOI 10.1177/1091581815584918.

Wikoff D, Thompson C, Perry C, White M, Borghoff S, Fitzgerald L, Haws LC. 2014. Development of toxicity values and exposure estimates for tetrabromobisphenol A [TBBPA]: Application in a margin of exposure assessment. J Appl Toxicol 35(11):1292-1308. doi: 10.1002/jat.3132.

Kerger BD, James RC, Galbraith DA. 2014. Tumors that mimic asbestos-related mesothelioma: Time to consider a genetics-based tumor registry? Frontiers in Genetics 5(151):1-14.

Proctor DM, Suh M. Campleman SL, Thompson CM. 2014. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicology 325:160-179.

Johnson GE, Soeteman-Hernandez, Gollapudi BB, Bodger OG, Dearfield KL, RH Heflich, Hixon JG, Lovell DP, MacGregor JT, Pottenger LH, Thompson CM, Abraham L, Thybaud V, Tanir JY, Zeiger E, van Benthem J, White PA. 2014. Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ Molec Mutagen 55(8):609-623. doi: 10.1002/em.21870/em.21870.

Lancaster JL, Antonijevic T, Starobin JM. 2014. Ordering and stability in lipid droplets with applications to low-density lipoproteins. Physical Review E89(6):062708.

Henderson R, Verougstraete V, Anderson K, Arbildua JJ, Brock TO, Brouwers T, Cappellini D, Delbeke K, Herting G, Hixon G, Wallinder IO, Rodriguez PH, Assche FV, Wilrich P, Oller AR. 2014. Interlaboratory validation of bioaccessibility testing for metals. Regul Toxicol Pharmacol 70(1):170-181. doi: 10.1016/j.yrtph.2014.06.02.

Faber W, Kirkpatrick D, Coder P, Li P, Borghoff S, Banton M. 2014. Subchronic, reproductive, and maternal toxicity studies with tertiary butyl acetate (TBAC). Regul Toxicol Pharmacol 68:332-342.

James RC, Britt J, Halmes N, Guzelian P. 2014. Comments on recent discussions providing differing causation methodologies. Hum Experim Toxicol 33(1):109-112.

Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, Van Der Kraak G, Wade MG and others. 2014. t4 Workshop report — Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. Altex 31(1):63-78.

Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Feinberg NN, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. 2014. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 20(23):6083–6095.

Song G, Petschauer JS, Madden AJ, Zamboni WC. 2014. Nanoparticles and the mononuclear phagocyte system: Pharmacokinetics and applications for inflammatory diseases. Curr Rheumatol Rev 10(1):22–34.

Yoon M, Efremenko A, Blaauboer B, Clewell HJ 3^rd. 2014. Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicol in Vitro 28(2):164–170.

Phillips MB, Yoon M, Young B, Tan Y-M. 2014. Analysis of biomarker utility using a PBPK/PD model for carbaryl. Front Pharmacol 5:246.

Suh M, Troese MJ, Hall DA, Yasso B, Yzenas JJ, Proctor DM. 2014. Evaluation of electric arc furnace-processed steel slag for dermal corrosion, irritation, and sensitization from dermal contact. J Appl Toxicol 34(12):1418-1425. DOI: 10.1002/jat.2974.

Bunch AG, Perry CS, Abraham L, Wikoff DS, Tachovsky JA, Hixon JG, Urban JD, Harris MA, Haws LC. 2014. Evaluation of impact of shale gas operations in the Barnett Shale region on volatile organic compounds in air and potential human health risks. Sci Tot Environ 468-469(2014):832-842.

Suh M, Abraham L, Hixon JG, Proctor D. 2014. The effects of perchlorate, nitrate, and thiocyanate on free thyroxine for potentially sensitive subpopulations of the 2001–2002 and 2007–2008 National Health and Nutrition Examination Surveys. J Expos Sci Epidemiol 24:579-587.

Urban JD, Wikoff DS, Bunch ATG, Harris MA, Haws LC. 2014. A review of background dioxin concentrations in urban/suburban and rural soils across the United States: Implications for site assessments and the establishment of soil cleanup levels. Sci Tot Environ 466-467:586-597.

Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays S, Hixon JG, Harris MA. 2014. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 34:525-536. doi: 10.1002/jat.2907.

Mahadevan B, Thorsrud BA, Brorby GP, Ferguson HE. 2014. A 3-week dietary safety study of octenyl succinic anhydride (OSA)-modified starch in neonatal farm piglets. Food Chem Toxicol 72:83-89.

Suh M, Thompson C, Kirman C, Carakostas M, Haws LC, Harris M, Proctor. 2014. High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice. Food  Chem Toxicol 65:381-388.

MacDonell MM, Haroun LA, Teuschler LK, Rice ER, Hertzberg RC, Butler JP, Chang Y, Clark S, Johns AP, Perry CS, Garcia SS, Jacobi JH, Scofield MA. 2013. Cumulative risk assessment toolbox: Methods and approaches for the practitioner. J Toxicol 2013:310904.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27. doi:pii: S0009-2797(13)00082-3. 10.1016/j.cbi.2013.04.003.

Dourson ML, Gadagbui B, Griffin S, Garabrant DH, Haws LC, Kirman C, Tohyama C. 2013. The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil. Regul Toxicol Pharmacol 66(2):208-216.

Hadley P, Petrisor IG. 2013. Incremental sampling: Challenges and opportunities for environmental forensics. Environ Foren 14(2):109–120.

O’Brien T, Ding H, Suh M, Thompson C, Parsons BL, Harris MA, Winkelman WA, Wolf JC, Hixon JG, Schwartz AM, Myers MB, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res 754:15-21. doi: 10.1016/j.mrgentox.2013.03.008

Rowlands JC, Budinsky R, Gollapudi B, Black MB, Wolfinger RD, Cukovic D, Bombkowski A, Thompson CM, Urban JD, Thomas RS. 2013. A genomics-based analysis of relative potencies of dioxin-like compounds in primary rat hepatocytes. Toxicol Sci 136(2):595-604.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3): 244-274.

Brorby GP, Sheehan PJ, Berman DW, Bogen KT, Holm SE. 2013. Exposures from chrysotile-containing joint compound: Evaluation of new model relating respirable dust to fiber concentrations. Risk Analysis 33(1): 161-176.

Urban JD, Carakostas MC, Brusick, DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51:386-390.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406.

Yoon M, Clewell HJ, and Andersen ME. 2013. Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. Toxicol in Vitro 27(1):11–15.

Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Mariggio MA, Onofrj M, Thomas A, Li H, Mangold JE, Signore AP, Demarco U, Demady DR, Nabili P, Lazrove E, Smith PJS, Gribkoff VK, Jonas EA. 2012. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 1446:1–11.

Kirman, CR, Hays, SM, Aylward, LL, Suh, M, Harris, MA, Thompson, CM, Haws, LC, Proctor, DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64.

Kopec AK, Thompson CM, Kim S, Forgacs AL, Zacharewski TR. 2012. Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelium. Toxicol Appl Pharmacol 262(2):124-138.

Katyal A, Petrisor IG. 2012. Innovative sustainable drought management strategy incorporating forensic techniques and policy framework. Environ Foren 13(2):122–139.

Kopec AK, Kim S, Forgacs AL, Zacharewski TR, Proctor DM, Harris MA, Haws LC, Thompson CM. 2012. Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. Toxicol Appl Pharmacol 259(1):13-26.

Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gürleyük H, Gerads R, Haws LC, Hays SM. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere 89(5): 487-493.

Thompson CM, Fedorov Y, Brown DD, Suh M, Proctor DM, Kuriakose L, Haws L, Harris MA. 2012. Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS ONE 7(8): e42720.

Thompson CM, Hixon JG, Proctor DM, Haws LC, Suh M, Urban JD,  Harris MA. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol 64(1): 68-76.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90.

Thompson CM, Proctor DM, Harris MA. 2012. Duodenal GSH/GSSG ratios in mice following oral exposure to Cr(VI). Toxicol Sci 126(1):287-288.

Yan GZ, Generaux CN, Yoon M, Goldsmith RB, Tidwell RR, Hall JE, Olson CA, Clewell HJ, Brouwer KL, Paine MF. 2012. A semi-physiologically-based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab Dispos 40:6–17.

Taylor M, Clewell HJ, Andersen ME, Schroeter JD, Yoon M, Keene AM, Dorman DC. 2012. Update on a pharmacokinetic-centric alternative Tier II program for MMT. Part II. Physiologically based pharmacokinetic modeling and manganese risk assessment. J Toxicol, Article ID 791431, 17 p.

Yoon M, Campbell J, Andersen M and Clewell H. 2012. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assays results. Crit Rev Toxicol 42(8):633–652.

Schroeter J, Dorman D, Yoon M, Nong A, Taylor M, Andersen M, Clewell H. 2012. Application of a multi-route physiologically-based pharmacokinetic model for manganese to evaluate dose-dependent neurological effects in monkeys. Toxicol Sci 129:432–446.

Song G, Wu H, Yoshino K, Zamboni WC. 2012. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 22(3):177–192.

Caron WP, Song G, Kumar P, Rawal S, Zamboni WC. 2012. Interpatient pharmacokinetic and pharmacodynamics variability of carrier-mediated anticancer agents in patients. Clin Pharmacol Ther
91(5):802–812.

Berman DW, Brorby GP, Sheehan PJ, Bogen KT, Holm SE. 2012. More on the dynamics of dust generation: The effects of mixing and sanding chrysotile, calcium carbonate, and other compounds on the characteristics of joint-compound dusts. Ann Occup Hyg 56(7):852-867.

Fowler, JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. 2012. Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane 5 serine mutations. Mol Pharmacol 81(6):820-831.

Henderson RG, Durando J, Oller A, Merkel DJ, Marone PA,  Bates HK. 2012. Acute oral toxicity of nickel compounds. Regul Toxicol Pharmacol 62(3):425-432.

Henderson RG, Cappellini D, Seilkop SK, Bates HK, Oller AR. 2012. Oral bioaccessibility testing and read-across hazard assessment of nickel compounds. Regul Toxicol Pharmacol 63(1):20-28.

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278.

McConkey DJ, White MC, Yan W. 2012. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 116:131-163.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG,  Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1): 58-70.

Bogen KT, Brorby GP, Berman DW, Sheehan PJ, Floyd M.  2011. Measuring mixed cellulose ester (MCE) filter mass under variable humidity conditions.  Ann Occup Hyg 55(5)485-494.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40.

Bussiere J, Leach M, Price K, Mounho B, Lightfoot-Dunn R. 2011. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay. Reg Toxicol Pharm 59(3):493-505.

Brorby GP, Sheehan PJ, Berman DW, Bogen KT, Holm SE. 2011. Potential artifacts associated with historical preparation of joint compound samples and reported airborne asbestos concentrations.  J Occup Environ Hyg 8(5):271–278.

Carakostas M. 2011. Long-term feeding effects of stevioside sweetener on some toxicological parameters of growing rats. J Appl Toxicol 31(6):595-596.

Gujral JS, Proctor DM, Su SH, and Fedoruk JM. 2011. Water adherence factors for human skin. Risk Analysis 31(8):1271-1280.

Miletich J, Eich G, Grampp G, and Mounho B. 2011. Guiding principles for a global “patients first” standard. mAbs 3(3):318-325.

Rowlands JC, Urban JD, Wikoff DS, Budinsky RA. 2011. An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor-interacting protein (AIP) gene. Drug Metab Pharmacokinet 26(4):431-439.

Sheehan PJ, Brorby GP, Berman DW, Bogen KT, Holm SE. 2011. Chamber for testing asbestos-containing products:  Validation and testing of a re-created chrysotile-containing joint compound.  Ann Occup Hyg 55(7):797-809.

Gentry PR, Clewell HJ 3rd, Clewell R, Campbell J, Van Landingham C, Shipp AM. 2011. Challenges in the application of quantitative approaches in risk assessment: A case study with di-(2-ethylhexyl)phthalate. Crit Rev Toxicol 41(Suppl 2):1–72.

Schroeter JD, Nong A, Yoon M, Taylor MD, Dorman DC, Andersen ME, and Clewell, HJ 3^rd. 2011. Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically-based pharmacokinetic models. Toxicol Sci 120(2):481–498.

Yoon M, Schroeter JD, Nong A, Taylor MD, Dorman DC, Andersen ME, and Clewell, HJ 3^rd. 2011. Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: Describing manganese homeostasis during development. Toxicol Sci 122: 297–316.

Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, Urban JD, Petrossians P, Elenkova AP, Tabarin A, Desailloud R, Maiter D, Schürrmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo Montañana C, Hana V, Halaby G, Delemer B, Labarta JI, Sonnet E, Ferrandez A, Hagelstein MTS, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. 2011. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509-515.

Urban JD, Rowlands JC, Budinsky RA. 2011. Single nucleotide polymorphisms in the human aryl hydrocarbon receptor nuclear translocator (ARNT) gene. Drug Metab Pharmacokinet 26(6):637-645.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271:299–308.

Buckley L, Chapman K, Burns Naas LA, Todd M, Martin P, Lansita J. 2011. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Int J Toxicol 30(5):583-590.

Franke K, Paustenbach D. 2011. Government and Navy knowledge regarding health hazards of asbestos: A state of the science evaluation (1900 to 1970). Inhal Toxicol 23(S3):1–20.

Hendler AH, Goodmanson Bunch AT, Crow WL. 2010. Long-term trends in ambient air 1,3-butadiene levels in Houston, Texas. Environ Sci Technol 44:7383-7390.

Birnbaum LS, Staskal-Wikoff D. 2010. 5th International PCB Workshop–Summary and implications. Environ Int 36(8):814-818.

Gatto NM, Kelsh MA, Mai DH, Suh M, Proctor DM. 2010. Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: A meta-analysis. Cancer Epidemiol 34(4):388-99.

Mounho B, Phillips A, Holcombe K, Grampp G, Lubiniecki T, Mollup I, Jones C. 2010. Global regulatory standards for the approval of biosimilars. Food Drug Law J 65(4):819-837.

Rowlands CJ, Staskal DF, GollapudI B, Budinsky R. 2010. The Human AHR: Identification of single nucleotide polymorphisms from six ethnic populations. Pharmacogenet Genomics 20(5):283-290.

Sheehan P, Bogen KT, Hicks J, Goswami E, Brorby G, Lau E, Ott B.  2010. Benzene inhalation of parts washers:  New estimates based on measures of occupational exposure to solvent coaromatics.  Risk Analysis 30(8):1249–1267.

Tachovsky JA, Urban JD, Wikoff DS, Haws LC, Harris MA. 2010. Reduction of a large fish tissue analyte database: identifying and assessing data specific to a remediation site for risk assessment application. Chemosphere 80(5):481-488.

Thompson CM, Grafström RC. 2010. Considerations for the implausibility of leukemia induction by formaldehyde. Toxicol Sci 120(1):230-232.

Zamboni WC, Wu H, La-Beck N, Gehrig P, Song G, Walsh M, Gabizon A, Ramanathan RK, Caron WP. 2010. Factors affecting the pharmacokinetics and pharmacodynamics of nanoparticle and nanosomal anticancer agents. E J Cancer Supplements 8(7):17.

Thompson CM, Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3.

Urban JD, Tachovsky JA, Haws LC, Wikoff Staskal D, Harris MA. 2010. Response to Mugdan et al.’s comment on Urban et al. “Assessment of Human Health Risks Posed by Consumption of Fish from the Lower Passaic River, New Jersey.” Sci Tot Environ 408(6):1468-1470.

Urban JD, Tachovsky JA, Haws LC, Staskal DF, and Harris MA. 2010. Response to Buchanan et al.’s comment on Urban et al. “Assessment of Human Health Risks Posed by Consumption of Fish from the Lower Passaic River, New Jersey.” Sci Tot Environ 408(8):2004-2007.

Driscoll SK, McArdle ME, Plumlee MH and Proctor D. 2010. Evaluation of hexavalent chromium in sediment pore water of the Hackensack River, New Jersey, USA. Environ Toxicol Chem 29(3):617-20.

Guzelian PS, Victoroff MS, Halmes C,  James RC. 2009. Clear path: Towards an evidence-based toxicology (EBT). Human & Exp Toxicol 28:71-79.

Oller AR, Cappellini D, Henderson RG, Bates HK. 2009. Temperature effect on nickel release in ammonium citrate.  J Environ Monit 11(9):1697-1699.

Oller AR, Cappellini D, Henderson RG, Bates HK. 2009. Comparison of nickel release in solutions used for the identification of water-soluble nickel exposures and in synthetic lung fluids. J Environ Monit 11(4):823–829.

Menzie CA, Ziccardi LM, Lowney YW, Fairbrother A, Shock SS, Tsuji JS, Hamai D, Proctor D, et al. 2009. Importance of considering the framework principles in risk assessment for metals. Environ Sci Technol 43(22):8478-8482.

Scott, LLF, Staskal, DF, Williams ES, Luksemburg WJ, Urban JD, Nguyen LM, Haws LC, Birnbaum LS, Paustenbach DJ, Harris MA. 2009. Levels of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in southern Mississippi catfish and estimation of potential health risks. Chemosphere 74(7):1002-10.

Thompson CM, Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53.

Thompson CM, Sonawane B, Grafström RC. 2009. The ontogeny, distribution and regulation of alcohol dehydrogenase 3: Implications for pulmonary physiology. Drug Metab Disposit 37(8):1565-1571.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health, Part B 12:1–24.

Yoon M, Nong A, Clewell HJ 3rd, Taylor MD, Dorman DC, Andersen ME. 2009. Lactational transfer of manganese in rats: Predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol Sci 112(1):23–43.

Yoon M, Nong A, Clewell HJ 3rd, Taylor MD, Dorman DC, Andersen ME. 2009. Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol Sci 112(1):44–58.

Urban, JD, Tachovsky JA, Staskal DF, Haws LC, Harris MA. 2009. Assessment of human health risks posed by consumption of fish from the Lower Passaic River, New Jersey. Sci Total Environ 408(2):209-224.

Carakostas MC, Curry LL, Boileau AC, Brusick DJ. 2008. Overview: The history, technical function and safety of rebaudioside A, a naturally occurring steviol glycoside, for use in food and beverages. Food Chem Toxicol 46(Suppl 7): S1-S10.

DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51:66–86.

Donovan E, Unice K, Roberts JD, Harris M, Finley B. 2008. Risk of gastrointestinal disease associated with exposure to pathogens in the water of the Lower Passaic River. Appl Environ Microbiol 74:994-1003.

Donovan EP, Staskal DF, Unice KM, Roberts JD, Haws LC, Finley BL, and Harris MA. 2008. Risk of gastrointestinal disease associated with exposure to pathogens in the sediments of the Lower Passaic River. Appl Environ Microbiol 74:1004-1018.

Haws LC, Tachovsky JA, Williams ES, Scott LF, Paustenbach D, Harris MA. 2008. Assessment of potential human health risks posed by benzene in beverages. J Food Sci 73(4):T33-T41.

James HR, Barfield L, Britt JK, James RC. 2008. Worker exposure to secondhand smoke: Evaluating a prediction model. Prof Saf Sep:34-44.

Makris SL, Thompson CM, Euling SY, Selevan SG, Sonawane B. 2008. A lifestage-specific spproach to hazard and dose-response characterization for children’s health risk assessment. Birth Defects Res Part B 83:530–546.

Richardson VM, Staskal DF, Ross DG, Diliberto JJ, Devito MJ, Birnbaum LS. 2008. Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. Toxicol Appl Pharmacol 226(3):244-250.

Yoon M, Barton HA. 2008. Predicting maternal rat and pup exposures: How different are they? Toxicol Sci 102(1):15–32.

Scott LLF, Harris MA, Unice KM, Scott P, Nguyen LM, Haws LC, and Paustenbach D. 2008. Addendum to: Evaluation of PCDD/F and dioxin-like PCB serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey of the United States population. J Exp Sci Env Epidemiol 18(5):524-532.

Scott PK, Proctor D. 2008. Soil suspension/dispersion modeling methods for estimating health-based soil cleanup levels of hexavalent chromium at chromite ore processing residue sites. J Air Waste Manag Assoc 58(3): 384-403.

Staskal DF, Scott LLF, Haws LC, Luksemburg WJ, Birnbaum LS, Nguyen LM, Urban JD, Williams ES, Paustenbach DJ, Harris MA. 2008. Assessment of polybrominated diphenyl ether exposures and health risks associated with consumption of southern Mississippi catfish. Environ Sci Technol 42(17):6755-6761.

Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM, White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Analysis 28(4):907–923.

Thompson CM, Subramaniam RP, Grafström RC. 2008. Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol 233(3):355–359.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health, Part B 11(7):519–547.

DeSesso JM, Watson RE, Keen CL, Hazelden KP, Haws LC, Li AA. 2008. Analysis and integration of developmental neurotoxicity and ancillary data into risk assessment: A case study of dimethoate. J Toxicol Environ Health A 72(2):94-109.

Balouet J-C, Oudijk G, Smith K, Petrisor IG, Grudd H, Stocklassa B. 2007. Applied dendroecology and environmental forensics. Characterizing and age dating environmental releases: Fundamentals and case studies. Environ Foren 8(1):1–17.

Ferriby LL, Knutsen JS, Harris MA, Unice KM, Scott P, Nony P, Haws LC, and Paustenbach D. 2007. Evaluation of PCDD/F and dioxin-like PCB serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey of the United States Population. J Exp Sci Environ Epidemiol 17:358-371.

Proctor DM, Gatto NM, Hong SJ, Allamneni KP. 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci. 98(2):313–326.

Simon T, Britt JK and James RC. 2007. Development of a neurotoxic equivalence scheme of relative potency for assessing the risk of PCB mixtures. Regul. Toxicol. Pharmacol. 48:148-170.

Thompson CM and Grafström RC. 2007. Mechanistic Considerations for Formaldehyde- Induced Bronchoconstriction Involving S-Nitrosoglutathione Reductase. Journal of Toxicology and Environmental Health, Part A. 71, 244–248.

Urban JD, Clarke WP, von Zastrow M, Kobilka B, Nichols DE, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, and Mailman RB. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol Exp Therap. 320 (1): 1-13.

Urban JD, Vargas G, von Zastrow M, and Mailman RB. 2007. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 32 (1): 67-77.

Lim SJ, Jung YS, Yoon MY, Kim YC. 2007. Comparative effects of dimethylsulfoxide on metabolism and toxicity of carbon tetrachloride and dichloromethane. J Appl Toxicol 27(1):25–31.

Yoon M, Madden MC, Barton HA. 2007. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: Impacts on metabolic parameter estimation and prediction of dose metrics. J Toxicol Environ Health, Part A 70:1527–1541.

Barone S Jr., Brown RC, Euling S, Cohen Hubal E, Kimmel CA, Makris S, Moya J, Selevan SG, Sonawane B, Thomas T, and Thompson CM. 2006. Visión General De La Evaluación Del Rieso En Salud Infantil Empleando Un Enfoque Por Etapas De Desarrollo. Acta Toxicol. Argent. 14(Sup), 7–10.

Becker DS, Long ER, Proctor DM, Ginn TC. 2006. Toxicity and bioavailability of chromium in sediments associated with chromite ore processing residue.  Environ Toxicol Chem. 25(10):2576–2583.

Haws LC, Su S, Harris MA, DeVito M, Walker N, Farland W, Finley B, and Birnbaum L. 2006. Development of a refined database of mammalian relative potency estimates for dioxin-like compounds. Toxicol Sci. 89(1):4-30.

Paustenbach DJ, Fehling K, Scott P, Harris M, and Kerger B. 2006. Identifying a soil clean-up criteria for dioxin in urban residential soils: How have 20 years of research and risk assessment experience affected the analysis? J Toxicol Environ Health, Part B. 9:87-145.

Staskal DF, Diliberto JJ and Birnbaum LS. 2006. Impact of repeated exposure on the toxicokinetics of BDE 47 in mice. Toxicol Sci. 89:380-5.

Staskal DF, Diliberto JJ, and Birnbam LS. 2006. Disposition of BDE 47 in developing mice. Toxicol Sci. 90:309-16.

Staskal DF, Hakk H, Bauer D, Diliberto JJ, and Birnbam LS. 2006. Toxicokinetics of Polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Toxicol Sci. 94:28-37.

Van den Berg M, Birnbaum L, Denison M, De Vito M, Farland W, Feeley M, Fiedler H, Hakansson H, Hanberg A, Haws LC, Rose M, Safe S, Schrenk D, Tohyama C, Tritscher A, Tuomisto J, Tysklind M, Walke Nr, and Peterson RE. 2006. The 2005 World Health Organization Reevaluation of Human and Mammalian Toxic Equivalency Factors for Dioxins and Dioxin-Like Compounds. Toxicol Sci. 93(2):223-241.

Yoon MY, Lee SJ, Lee BH, Chung JH, Kim YC. 2006. Effects of dimethylsulfoxide on metabolism and toxicity of acetaminophen in mice. Biol Pharmaceut Bull 29(8):1618–1624.

Yoon M, Madden MC, Barton HA. 2006. Developmental expression of aldehyde dehydrogenase in rat: A comparison of liver and lung development. Toxicol Sci 89(2):386–398.

Gwak HS, Park KH, Choi JS, Song G, Sung MK, Jang JO. 2005. Determination of ethambutol in human plasma by a validated HPLC method and its application to single-dose pharmacokinetics. J Kor Pharm Sci 35(2):123–127.

Garabrant G and RC James RC. 2005. Trichloroethylene and cancer in humans: Recognizing the need for an evidence based analysis. Toxicology. 212:80-84.

Grasty RC, Bjork JA, Wallace KB, Wolf DC,  Lau CS, Rogers JM. 2005. Effects of prenatal perfluorooctane sulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res B Dev Reprod Toxicol. Oct; 74(5):405-16.

Guzelian PS, Victoroff M, Halmes NC, James RC and Guzelian CP. 2005. Evidence-based toxicology: A comprehensive framework for causation. Hum. Exp. Toxicol. 24:161-201.

Staskal DF, Diliberto JJ, DeVito MJ and Birnbaum LS. 2005. Inhibition of Human and Rat CYP1A2 by TCDD and Dioxin-like Chemicals. Toxicol Sci. 84: 225-31.

Staskal DF, Diliberto JJ, DeVito MJ, and Birnbaum LS. 2005. Toxicokinetics of BDE 47 in Female Mice: Effects of Dose, Route of Exposure, and Time. Toxicol Sci. 83: 215-23.

Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB. 2004. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol. 66 (1): 97 – 105.

Proctor DM, Panko JP, Liebig EW, Paustenbach, DJ. 2004. Estimating historical occupational exposure to airborne hexavalent chromium in a chromate production plant: 1940–1972. Occup Environ Hyg. 1:752–767.

Schecter, A, Papke O, Tung KC, Staskal DF, and Birnbaum L. 2004. Polybrominated diphenyl ether contamination of United States food. Environ Sci Technol. 38(20): 5306-11.

Thompson CM, Wojno H, Greiner E, May EL, Rice KC, and Selley DE. 2004. Activation of G-proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors. Journal of Pharmacology and Experimental Therapeutics. 308(2), 547–554.

Warren DA, Kerger BD, Britt JK and James RC. 2004. Development of an oral cancer slope factor for Aroclor 1268. Regul. Toxicol. Pharmacol. 40:42-53.

Kim HR, Chung SY, Jeong YH, Go EJ, Han AR, Kim NH, Sung MK, Song G, Jang JO, Nam JW, Lee HJ, Seo EK. 2004. P-glycoprotein inhibitory activity of Indonesian medicinal plants in human breast cancer cells. Nat Product Sci 10(6):268–271.

Birnbaum LS, and Staskal DF. 2004. Brominated Flame Retardants: Cause for Concern? Environ Health Perspect. 112: 9-17.

Demady DR, Lowe ER, Everett AC, Billecke SS, Kamada Y, Dunbar AY, Osawa Y. 2003. Metabolism-based inactivation of neuronal NO-synthase by components of cigarette and cigarette smoke. Drug Metab Disposit 31(7):1–6.

Birnbaum LS, Staskal DF, and Diliberto JJ. 2003. Health effects of polybrominated dibenzo-p-dioxins (PBDDs) and dibenzofurans (PBDFs). Environ Inter. 29: 855-860.

Crump C, Crump KS, Hack E, Luippold RS, Mundt KA, Panko JP, Liebig EW, Paustenbach DJ, Proctor DM. 2003. Dose-response and risk assessment of airborne hexavalent chromium and lung cancer mortality. Risk Anal. 23(6):1155−1171.

Grasty RC, Grey BE, Wolf DC,  Lau CS, Rogers JM. 2003. Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res (Part B) Dev Reprod Toxicol. Dec;68(6):465-71.

Luippold RS, Mundt KA, Austin RP, Liebig E, Panko JP, Crump C, Crump K, Proctor DM. 2003. Lung cancer mortality among chromate workers. 2003. Occup Environ Med. 60:451−457.

Proctor D, Panko J, Liebig E, Mundt K, Buczynski M, Barnhart R, Harris MA, Morgan R, Finley B, and Paustenbach D. 2003. Workplace concentrations of airborne hexavalent chromium for the Painesville, Ohio chromate production plant. Appl Occ Environ Hyg J. 18(6):430-449.

Scott P, Petura J, and Harris MA. 2003. Derivation of a liquid to solid ratio for ASTM method D3987 85 for soils containing chromite ore processing residue using selected unsaturated zone models. Soil Sed Contam. 12(4):443-480.

Demady DR, Jianmongkol S, Vuletich JL, Bender AT, Osawa Y. 2002. Irreversible inactivation of neuronal nitric oxide synthase by agmatine, an endogenous amine formed by decarboxylation of arginine. Molec Pharmacol 59(1):1–6.

Grant RL, Rodriguez R, Hofelt CS, and Haws LC. 2002. Shortcomings in USEPA’s approach for predicting risk due to consumption of animal food products impacted by air emissions from hazardous waste combustion facilities: a case study involving phthalates. Human Ecol Risk Assess. 8(5):1137-1154.

Roberts SM, Jordan KE, Warren DA, Britt JK and James RC. 2002. Evaluation of the carcinogenicity of 1,1-Dichloroethylene (Vinylidene Chloride). Regul. Toxicol. Pharmacol. 35:44-55.

Merok, JR, Lansita, JA, Tunstead, JR, Sherley, JL. 2002. “Cosegregation of Chromosomes Containing Immortal DNA Strands in Cells that Cycle with Asymmetric Stem Cell Kinetics,” Cancer Res., 62, 6791-6795.

Hofelt CS, Honeycutt M, McCoy JT, and Haws LC. 2001. Development of a metabolism factor for polycyclic aromatic hydrocarbons for use in multipathway risk assessments for hazardous waste combustion facilities. Reg Toxicol Pharmacol. 33:60-65.

Strobel HW, Thompson CM, Antonovic L. 2001. Cytochromes P450 in brain: function and significance. Current Drug Metabolism. 2(2), 199–214.

Yoon M, Park S, Park T. 2001. Stress-induced changes of taurine transporter activity in the human colon carcinoma cell line (HT-29). Korean J Nutr 34(2):150–157.

Yoon M, Jung H, Lee H, Park T. 2001. Beta-alanine induced down-regulation of the taurine transporter activity in the human colon carcinoma cell line (HT-29). J Korean Soc Food Sci Nutr 30(2):314–319.

Noguchi S, Jianmongkol S Bender AT, Kamada Y, Demady DR, Osawa Y. 2000. Guanabenz-mediated inactivation and enhanced proteolytic degradation of neuronal nitric oxide synthase. J Biol Chem 275(4):2376–2380.

Jianmongkol S, Vuletich JL, Bender AT, Demady DR, Osawa Y. 2000. Aminoguanidine-mediated inactivation and alteration of neuronal nitric oxide synthase. J Biol Chem 275(18):13370–13376.

Bender AT, Demady DR, Osawa Y. 2000. Ubiquitination of neuronal nitric oxide synthase in vitro and in vivo. J Biol Chem 275(23):17407–17411.

Finley BL, Proctor DM, Harris MA, and Fowler JF. 2000. Letter to the editor. American J Contact Derm. 123-125.

Smith DM, Grasty RC, Theodosiou NA, Tabin CJ, Nascone-Yoder NM.  2000. Evolutionary relationships between the amphibian, avian, and mammalian stomachs.  Evol Dev. Nov-Dec;2(6):348-59.

Thompson CM, Capdevila JH, and Strobel HW. 2000. Recombinant P450 2D18 Metabolism of Dopamine and Arachidonic Acid. Journal of Pharmacology and Experimental Therapeutics. 294(3), 1120–1130.

Kim SK, Kim SY, Yoon MY, Oh SJ, Kim HS, Lee JY, Kang SA, Lee KH, Kim YC. 2000. Chronic toxicity of a combined preparation of ticlopidine and Ginkgo biloba extract (EGb) orally administered to rats for 13 consecutive weeks. J Toxicol Public Health 16(4):293–301.

Kim SN, Kim SY, Yim HK, Lee WY, Ham KS, Kim SK, Yoon MY, Kim YC. 1999. Effect of dimethyl-4, 4’-dimethoxy-5, 6,5’, 6’-dimethylenedioxybipheny-2,2′-dicarboxylate (DDB) on chemical-induced liver injury. Biol Pharmaceut Bull 22(1):93–95.

Gerhardt B, Kordas TJ, Thompson CM, Patel P, and Vida TV. 1998. The vesicle transport protein, Vps33p, is an ATP binding protein that localizes to the cytosol in an energy dependent manner. Journal of Biological Chemistry. 273(25), 15818–15829.

Thompson CM, Kawashima H, and Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Archives of Biochemistry and Biophysics. 359(1), 115–121.

Yim HK, Kim SN, Kim SK, Kim SY, Yoon MY, Kang SA, Kim YC. 1998. Acute oral toxicity of a combined preparation of ticlopidine and Ginkgo biloba extract in rats. J Toxicol Public Health 14(1):119–122.

Kim SY, Yim HK, Yoon MY, Kim SK, Lee JY, Oh SJ, Kim HS, Kang SA, Kim YC. 1998. Subchronic toxicity of a combined preparation of ticlopidine and Ginkgo biloba extract orally administered to rats for 30 days. J Toxicol Public Health 14(4):547–555.

Costa M, Zhitkovich A, Harris MA, Paustenbach D, and Gargas M. 1997. DNA-Protein crosslinks produced by various chemicals in cultured human lymphocytes. J Toxicol Environ Health.

Kawashima H, Kusunose E, Thompson CM, and Strobel HW. 1997. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Archives of Biochemistry and Biophysics. 347(1), 148–154.

Roberts SM, DeMott R and James RC. 1997. Adrenergic modulation of hepatotoxicity.  Drug Metab. Rev. 29: 329-353.

Calabrese EJ, Stanek EJ, James RC and Roberts SM. 1997. Soil ingestion: A concern for acute toxicity in children.  Environ. Health Perspect. 105:1354-1358.

Scott P, Finley B, Harris MA, and Rabbe D. 1997. Determination of background airborne hexavalent chromium concentrations in industrial areas. J Air Waste Manage. Assoc. 47:592-600.

Thompson CM, Bernhard AE, and Strobel HW. 1997. Barbiturate-induced expression of neuronal nitric oxide synthase in the rat cerebellum. Brain Research. 754, 142–146.

Yoon MY, Kim YC. 1997. Acute toxicity of pectenotoxin 2 and its effects on hepatic metabolizing enzyme system in mice. Korean J Toxicol 13(3):183–186.

Yoon MY, Kim SN, Kim YC. 1997. Potentiation of acetaminophen hepatotoxicity by acute physical exercise in rats. Res Comm Molec Pathol Pharmacol 96(1):35–44.

Yoon MY, Kim YC. 1997. Toxicity and changes in hepatic metabolizing enzyme system induced by repeated administration of Pectenotoxin 2 isolated from marine sponges. Korean J Pharmacol 28(4):280–285.

Ramu K, Perry CS, Ahmed T, Pakenham G, and Kehrer JP. 1996. Studies on the basis for the toxicity of acrolein mercapturates.  Toxicology and Applied Pharmacology. 140(2):487-498.

Sauers L and Perry C.1996. Regulatory affairs – a growing opportunity for toxicologists. SOT Communiqué, May/June 1996.

Huber KM, Mauk MD, Thompson CM, and Kelly PT. 1995. A critical period of protein kinase activity after tetanic stimulation is required for the induction of long-term potentiation. Learning & Memory. 2, 81–100.

Perry CS, Liu XL, Lund LG, and Kehrer JP. 1995. Differential toxicities of cyclophosphamide and its glutathione metabolites to A549 cells. Toxicol. in Vitro. 9:21-26.

Roberts SM, Harbison RD, Westhouse RA and James RC. 1995. Exacerbation of carbon tetrachloride ¬induced liver injury in the rat by methamphetamine.  Toxicol. Lett. 76:77–83.

Roberts SM, Harbison RD and James RC. 1995. Mechanistic studies on the potentiation of carbon tetrachloride hepatotoxicity by methamphetamine.  Toxicology 97:49–57.

Williams CA, James RC and Freeman RW. 1995. Using the EPC approach to develop health based soil and water concentrations for environmental chemicals. Regul. Toxicol. Pharmacol. 22:64–75.

Borgert CJ, S.M. Roberts SM, Harbison RD and James RC. 1995. Influence of soil half–life on risk assessment of carcinogens. Regul. Toxicol. Pharmacol. 22:143–151.

Gargas M, Norton R, Harris MA, Paustenbach D, and Finley B. 1994. Urinary excretion of chromium following ingestion of chromite ore processing residue in humans: implications for biomonitoring. Risk Anal. 14(6):1019-1024.

Haws LC, Jackson BA, Turnbull D, and Dressler WE. 1994. Two approaches for assessing human cancer risk from disperse blue 1. Reg Toxicol Pharmacol. 19:80-96.

James RC, Roberts SM and Williams PL. 1994. Evaluation of the adequacy of the Threshold Limit Value for cyclonite.  Appl. Occup. Environ. Hyg. 9:485–492.

Roberts SM, Harbison RD and James RC. 1994. Methamphetamine potentiation of carbon tetrachloride hepatotoxicity in mice.  J. Pharmacol. Exp. Ther. 271:1051–1057.

Roberts SM, Harbison RD, Roth L and James RC. 1994. Methylphenidate–induced hepatotoxicity in mice and its potentiation by alpha-adrenergic agonist drugs.  Life Sci. 55:269-281.

Williams CA, Jones HD, Freeman RW, Wernke MJ, Williams PL, Roberts SM and James RC. 1994. The EPC approach to estimating safety from exposure to environmental chemicals.  Regul. Pharmacol. Toxicol. 20:259–280.

Yoon MY, Kim YC. 1994. Effects of acute physical exercise on acetaminophen hepatotoxicity in female rats. Korean J Toxicol 10(2):333–340.

Copeland TL, Paustenbach DJ, Harris MA, and Otani J. 1993. Comparing the results of a Monte Carlo analysis with EPA’s reasonable maximum exposed individual (RMEI): a case study of a former wood treatment site. Reg Toxicol Pharmacol. 18:275-312.

Harris, MA, Zacharewski T, and Safe S. 1993. Comparative potencies of Aroclors 1232, 1248, 1254, and 1260 in male wistar rats—Assessment of the toxic equivalency factor (TEF) approach for polychlorinated biphenyls (PCBs). Fund Appl Toxicol. 20:456-463.

James RC, Busch H, Tamburro CH, Harbison RD, Schell JD and Roberts SM. 1993. Polychlorinated biphenyl exposure and human disease.  J. Occup. Med. 35:136–148.

James RC, Harbison RD and Roberts SM. 1993. Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity:  Evidence for a glutathione-dependent mechanism.  Toxciol.  Appl. Pharmacol. 118:159–168.

Roberts SM, Munson JW, James RC and Harbison RD. 1992. An assay for cocaethylene and other cocaine metabolites in liver using high-performance liquid chromatography.  Anal. Biochem. 202:256-261.

Roth L, Harbison RD, James RC, Tobin T and Roberts SM. 1992. Cocaine hepatotoxicity: Influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis.  Hepatology 15:934-940.

Roberts SM, Roth L, Harbison RD and James RC. 1992. Cocaethylene hepatotoxicity in mice.  Biochem. Pharmacol. 43:1989-1995.

Milner GC, James RC and Nye AC. 1992. Human health-based soil cleanup guidelines for diesel fuel No. 2.  J. Soil Contam. 1:103-158.

Wenning RJ, Harris MA, Ungs MJ, Paustenbach DJ, and Bedbury H. 1992. Chemometric comparison of polychlorinated dibenzo-p-dioxin and dibenzofuran residues in surficial sediments from Newark Bay, New Jersey and other industrialized waterways. Arch Environ Contam Toxicol. 22:397-413.

Wenning RJ, Harris MA, Paustenbach DJ, and Bedbury H. 1992. Potential sources of 1,2,8,9-tetrachlorodibenzo-p-dioxin in the aquatic environment. Ecotoxicol Environ Safety. 23(2):133-146.

Zacharewski T, Harris MA, Biegel L, Morrison V, Merchant M, and Safe S. 1992. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. Toxicol Appl Pharmacol. 113:311-318.

Couture-Haws L, Harris MW, Lockhart AC, and Birnbaum LS. 1991. Evaluation of the persistence of hydronephrosis induced in mice following in uteri and/or lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 107:402-412.

Couture-Haws L, Harris MW, McDonald MM, Lockhart AC, and Birnbaum LS. 1991. Hydronephrosis in mice exposed to TCDD-contaminated breast milk: identification of the peak period of sensitivity and assessment of potential recovery. Toxicol Appl Pharmacol. 107:413-428.

Frankos VH, Schmitt DF, Haws LC, McEvily AJ, Iyengar R, Miller SA, Munro IC, Clydsdale FM, Forbes AL, and Sauer RM. 1991. Generally recognized as safe (GRAS) evaluation of 4-hexylresorcinol for use as a processing aid for the prevention of melanosis in shrimp. Reg Toxicol Pharmacol. 14:202-212.

Piskorska-Pliszczynska, J, Astroff B, Zacharewski T, Harris MA, Rosengren R, Morrison V, Safe L, and Safe S. 1991. Mechanism of action of 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists: characterization of 6-[125I]methyl-8-iodo-1,3-dichlorodibenzofuran-Ah receptor complexes. Arch Biochem Biophy. 284(1):193-200.

Safe S, Astroff B, Harris MA, Zacharewski T, Dickerson R, Romkes M, and Biegel L. 1991. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens: characterization and mechanism of action. Pharmacol Toxicol. 69:400-409.

Safe S, Harris MA, Biegel L, and Zacharewski T. 1991. Mechanism of Action of TCDD as an antiestrogen in transformed human breast cancer and rodent cell lines. Banbury Report 35: Biological Basis for Risk Assessment of Dioxins and Related Compounds Cold Spring Harbor Laboratory Press. 367-377.

Simmons HF, James RC, Harbison RD, Patel DG and Roberts SM. 1991. Examination of the role of catechotamines in hepatic glutathione suppression by cold-restraint in mice.  Toxicology 67:29–40.

Harbison RD, James RC and Roberts SM. 1991. Hepatic glutathione suppression by alpha-adrenoreceptor agonist compounds.  Toxicology 69:279-290.

Roberts SM, Harbison RD, Seng JE and James RC. 1991. Potentiation of carbon tetrachloride hepatotoxicity by phenylpropanolamine.  Toxicol. Appl. Pharmacol. 111:175-188.

Roberts SM, Harbison RD and James RC. 1991. Human microsomal N-oxidative metabolism of cocaine.  Drug Metab. Dispos. 19:1046-1051.

Zacharewski T, Harris MA, and Safe S. 1991. Evidence for a possible mechanism of action of the 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decrease of nuclear estrogen receptor levels in wild-type and mutant Hepa 1c1c7 cells. Biochem Pharmacol. 41:1931-1939.

Couture-Haws L, Abbott BD, and Birnbaum LS. 1990. A critical review of the developmental toxicity and teratogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: recent advances in understanding the mechanism. Teratol. 42:619-627.

Couture, LA, Harris MW, and Birnbaum LS. 1990. Characterization of the peak period of sensitivity for the induction of hydronephrosis in C57BL/6N mice following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam Appl Toxicol. 15:142-150.

Harris MA, Piskorska-Pliszczynska J, Zacharewski T, and Safe S. 1990. Human breast cancer cell lines as models for investigating the effects of TCDD and related compounds. Chemosphere. 20(7-9):1135-1140.

Harris MA, Zacharewski T, Piskorska-Pliszcyznska J, Rosengren R, and Safe S. 1990. Structure-dependent induction of aryl hydrocarbon hydroxylase activity in C57BL/6 Mice by 2,3,7,8-tetrachlordibenzo-p-dioxin and related congeners: mechanistic studies. Toxicol Appl Pharmacol. 105:243-253.

Harris MA, Zacharewski T, and Safe S. 1990. Effects of 2,3,7,8-tetrachorodibenzo-p-dioxin and related compounds on the occupied nuclear estrogen receptor in MCF-7 human breast cancer cells. Cancer Res. 50:3579-3584.

Randerath K, Putman KL, Randerath E, Harris MA, Zacharewski T, and Safe S. 1990. Effects of 2,3,7,8-TCDD and related compounds on the levels of age-dependent I-spot DNA adducts in the liver of female and male Sprague-Dawley rats. Chemosphere. 20(7-9):1049-1052.

Randerath K, Putman KL, Randerath E, Zacharewski T, Harris MA, and Safe S. 1990. Effects on 2,3,7,8-tetrachlorodibenzo-p-dioxin on I-compounds in hepatic DNA of Sprague-Dawley rats: sex specific effects and structure-activity relationships. Toxicol Appl Pharmacol. 103:271-280.

Roberts SM, Pounds JG and James RC. 1990. Cocaine toxicity in cultured rat hepatocytes.  Toxicol. Lett. 50: 283-288.

Simmons HF, James RC, Harbison RD and Roberts SM. 1990. Depression of glutathione by cold-restraint in mice.  Toxicology 61:59-71.

Safe S, Harris MA, Zacharewski T, and Biegel L. 1990. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as an antiestrogen in human breast cancer cells: mechanistic studies. Proceedings Dioxin `90, Eco-Informa Press. Bayreuth, Germany, 1:137-140.

Biegel L, Harris MA, Davis D, Rosengren R, Safe L, and Safe S. 1989. 2,2′,4,4′,5,5′-hexachlorobiphenyl as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL/6J mice. Toxicol Appl Pharmacol. 97:561-571.

Birnbaum LS, Couture LA, and Elwell MR. 1989. Subchronic effects of exposure to Octachlorodibenzo-p-dioxin (OCDD). Chemosphere. 18(1-6):389-390.

Couture LA, Harris MW, and Birnbaum LS. 1989. Developmental toxicity of 2,3,4,7,8-pentachlorodibenzofuran (4-PeCDF) in the Fischer 344 rat. Fundam Appl Toxicol. 12:358-366.

Harris, MA, Piskorska-Pliszczynska J, Zacharewski T, Romkes M, and Safe S. 1989. Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor. Cancer Res. 49:4531-4535.

Harris MA, Zacharewski T, Astroff B, Kamps C, and Safe S. 1989. Characterization of 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) as a 2,3,7,8-TCDD antagonist in male rats: induction of monooxygenases. Chemosphere. 19:769-772.

Harris MA, Zacharewski T, Astroff B, and Safe S. 1989. Partial antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzofuran: mechanistic studies. Mol Pharmacol. 35:729-735.

Kerger BD, Roberts SM, Harbison RD and James RC. 1989. Antagonism of bromobenzene-induced hepatotoxicity by the a-adrenoreceptor blocking agents, phentolamine and idazoxan: Role of hypothermia.  Toxicol. Appl. Pharmacol. 97:360-369.

Skoulis NP, James RC, Harbison RD and Roberts SM. 1989. Depression of hepatic glutathione by opioid analgesic drugs in mice.  Toxicol. Appl. Pharmacol. 99:139-147.

Skoulis NP, James RC, Harbison RD and Roberts SM. 1989. Perturbation of glutathione by a central action of morphine.  Toxicology. 57:287-302.

Clevenger MA, Roberts SM, Lattin DL, Harbison RD and James RC. 1989. The pharmacokinetics of 2,2’,5,5’-tetrachlorobiphenyl and 3,3’,4,4’-tetrachlorobiphenyl and its relationship to toxicity.  Toxicol. Appl. Pharmacol. 100:315-327.

Safe S, Mason G, Sawyer T, Zacharewski T, Harris MA, Yao C, Keys B, Farrell K, Holcomb M, Davis D, Safe L, Piskorska-Pliszcyzynska J, Leece B, Denomme M, Hutzinger O, Thoma H, Chittim B, and Madge J. 1989. Development and validation of in vitro induction assays for toxic halogenated aromatic mixtures: a review. Toxicol Ind Health. 5(5):757-775.

Safe S, Zacharewski T, Safe L, Harris MA, Yao C, and Holcomb M. 1989. Validation of the AHH induction bioassay for the determination of 2,3,7,8-TCDD toxic equivalents. Chemosphere. 18(1-6):941-946.

Zacharewski T, Harris MA, and Safe S. 1989. Induction of cytochrome P450-dependent monooxygenase activities in rat hepatoma H-4-IIE cells in culture by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds: mechanistic studies using radiolabeled congeners. Arch Biochem Biophys. 272(2):344-355.

Zacharewski T, Harris MA, Safe S, Thoma H, Hauschulz G, Knorr E, and Hutzinger O. 1989. Application of the in vitro AHH induction bioassay for determining 2,3,7,8-TCDD equivalents: pyrolyzed flame retardant mixtures. Chemosphere. 18(1-6):383-387.

Birnbaum LS and Couture LA. 1988. Disposition of Octachlorodibenzo-p-dioxin (OCDD) in male rats. Toxicol Appl Pharmacol. 93:22-30.

Couture LA, Elwell MR, and Birnbaum LS. 1988. Dioxin-like effects observed in male rats following exposure to Octachlorodibenzo-p-dioxin (OCDD) during a 13-week study. Toxicol Appl Pharmacol. 93:31-46.

Harris MA, Kamps C, and Safe S. 1988. Role of the 4-5S binding protein in the induction of aryl hydrocarbon hydroxylase in the rat. Carcinogenesis. 9(8):1475-1479.

Smith AC, Roberts SM, Berman LM, Harbison RD and James RC. 1988. Effects of piperonyl butoxide on halothane hepatotoxicity and metabolism in the hyperthyroid rat.  Toxicology. 50: 95-105.

James RC, Wessinger WD, Roberts SM, Millner GC and Paule MG. 1988. Centrally mediated opioid induced depletion of hepatic glutathione: Effects of intracerebroventricular administration of mu, kappa, sigma and delta agonists.  Toxicology 51:267-279.

Smith AC, Roberts SM, James RC, Berman LM and Harbison RD. 1988. Comparison of covalent binding from halothane metabolism in hepatic microsomes from phenobarbital-induced and hyperthyroid rats.  Xenobiotica. 18: 991-1001.

Kerger BD, James RC and Roberts SM. 1988. An assay for phentolamine using high performance liquid chromatography with electrochemical detection.  Anal. Biochem. 170:145-151.

Kerger BD, Gandy J, Bucci TJ, Roberts SM, Harbison RD and James RC. 1988. Antagonism of bromobenzene-induced hepatotoxicity by the alpha-adrenergic blocking agents, phentolamine and idazoxan.  Toxicol. Appl. Pharmacol. 95: 12-23.

Kerger BD, Roberts SM, Hinson JA, Gandy J, Harbison RD and James RC.  1988. Antagonism of bromobenzene-induced hepatotoxicity by phentolamine:  Evidence for a metabolism independent intervention.  Toxicol.  Appl. Pharmacol. 95: 24-31.

Kerger BD, Robert SM and James RC.  1988. Comparison of human and mouse liver microsomal metabolism of bromobenzene and chlorobenzene to 2- and 4-halophenols.  Drug Metab. Dispos. 16:672-677.

Zacharewski T, Harris MA, Safe S, Thoma H, and Hutzinger O. 1988. Applications of the in vitro aryl hydrocarbon hydroxylase induction assay for determining “2,3,7,8-tetrachlorodibenzo-p-dioxin equivalents”: pyrolyzed brominated flame retardants. Toxicology. 51:177-189.

Robert SM, Grund VR, James RC and Harbison RD.  1987. Histamine and hepatic glutathione in the mouse.  Life Sci. 40:2103-2110.

James RC, Schiefer MA, Roberts SM and Harbison RD. 1987. Antagonism of cocaine-induced hepatotoxicity by the a-adrenergic antagonists phentolamine and yohimbine.  J. Pharmacol. Exp. Ther. 242:726-732.

Roberts SM, Skoulis NP and James RC.  1987. A centrally mediated effect of morphine to diminish hepatocellular glutathione.  Biochem. Pharmacol. 36:3001-3005.

Roberts SM, James RC, Simmons HF and Harbison RD. 1987. Alcohol and cocaine-induced liver injury.  Alcohol Health Res. World. 11:20-25.

James RC, Freeman RW and Harbison RD. 1984. L-alpha-acetylmethadol- induced tissue alterations in mice.  Drug Chem. Toxicol. 7:91-112.

Smith AC, James RC, Berman LM and Harbison RD. 1984. Paradoxical effects of perturbation of intracellular levels of glutathione on halothane-induced hepatotoxicity in hyperthryoid rats.  Fundam. Appl. Toxicol. 4:221-230.

James RC, Roberts SM and Harbison RD. 1983. The perturbation of hepatic glutathione by alpha-2 adrenergic agonists.  Fundam. Appl. Toxicol. 3:303-308.

Smith A, Berman LM, James RC and Harbison RD. 1983. Characterization of hyperthyroidism enhancement of halothane-induced hepatotoxicity.  Biochem. Pharmacol. 32:3531-3539.

James RC and Harbison RD. 1982. Hepatic glutathione and hepatotoxicity:  Effects of cytochrome P-450 complexing compounds SKF525-A, L-alpha acetamethadol (LAAM), norLAAM, and piperonyl butoxide.  Biochem. Pharmacol. 31:1829-1835.

James RC, Goodman DR and Harbison RD. 1982. Hepatic glutathione and hepatotoxicity:  Changes induced by selected narcotics.  J. Pharmacol. Exp. Ther. 221:708-714.

Goodman DR, James RC and Harbison RD. 1982. Placental Toxicology.  Food. Chem. Toxicol. 20:123-128,  1982.

Kupfer A, James RC, Carr K and Branch R. 1982. Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography.  J. Chromatogr. 232:93-100.

Desmond PV, James RC, Schenker S and Branch RA. 1981. Preservation of glucuronidation in carbon tetrachloride-induced acute liver injury in the rat.  Biochem. Pharmacol. 30:993-999.

James RC, Villenevue JP, Kupfer AH and Branck RA. 1981. Induction of drug-metabolizing enzymes by the enantionmers of normephenytoin in the rat.  Drug Metab. Dispos. 9:297-302.

James RC, Desmond PV, Kupfer A, Schenker S and Branch RA. 1981. The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene.  J. Pharmacol. Exp. Ther. 217:127-132.

Verbeeck R, James RC, Taber DF, Sweetman B and Wilkinson GR. 1980. The determination of meperdine, normeperidine and deuterated analogs in blood and plasma by gas chromatography mass spectrometry selected ion monitoring.  Biomed. Mass Spectrom. 7:58-60.

James RC and Franklin MR.  The triphasic amphetamine lethal dose curve in mice and its possible relationship to drug metabolism.  Toxicol. Appl. Pharmacol. 44:63-73.

James RC and Franklin MR. 1978. Tissue concentrations and the mortality of d-amphetamine in mice:  Change associated with the use of diethaminoethyl 2,2. diphenylvalerate. HCI.  Toxicol. Appl. Pharmacol. 44:75-80.

James RC and Franklin MR. 1975. Comparisons of the formation of cytochrome P-450 complexes absorbing at 455 n.m. in rabbit and rat microsomes.  Biochem. Pharmacol. 24:835-838.